Deng Ying-Fang, Zhao Ya-Qi, Wang Liang, Cui Xian-Shu
Department of Oncology, Affiliated Hospital of Qinghai University, Xining 810000, Qinghai Province, China.
Graduate School of Qinghai University, Affiliated Hospital of Qinghai University, Xining 810000, Qinghai Province, China.
World J Gastrointest Surg. 2025 Jun 27;17(6):101206. doi: 10.4240/wjgs.v17.i6.101206.
We editorialized on this study published by Zou . Gastrointestinal bleeding is a common clinical symptom, and hemocoagulase is frequently used to treat hemorrhagic conditions. However, studies have shown that hemocoagulase treatment may induce acquired hypofibrinogenemia, further aggravating the bleeding. Zou retrospectively analyzed 109 gastrointestinal bleeding cases to explore the hazards underlying hypofibrinogenemia induced by hemocoagulase, and identified higher total dose of hemocoagulase and female sex, as well as low baseline fibrinogen levels as significant hazards. Consequently, clinicians should be aware of both intrinsic and extrinsic risk factors when using hemocoagulase among this patient population, and remain vigilant for the potential development of hemocoagulase-induced hypofibrinogenemia.
我们针对邹发表的这项研究发表了社论。消化道出血是一种常见的临床症状，血凝酶常用于治疗出血性疾病。然而，研究表明，血凝酶治疗可能会诱发获得性低纤维蛋白原血症，进而加重出血。邹回顾性分析了109例消化道出血病例，以探究血凝酶诱发低纤维蛋白原血症的潜在危害，并确定血凝酶的总剂量较高、女性以及低基线纤维蛋白原水平是显著危害因素。因此，临床医生在该患者群体中使用血凝酶时应意识到内在和外在的风险因素，并对血凝酶诱发的低纤维蛋白原血症的潜在发展保持警惕。
